Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Cancer Res. 2011 Jul 20;71(18):5965–5975. doi: 10.1158/0008-5472.CAN-11-0445

Figure 6.

Figure 6

(A) Quantitative analyses of E545K peptide targeted by mass spectrometry from the MCF7 cells and from SKBR3 and BT-474 cells engineered to express the WT (WT) p110α or the E545K mutant. (B) H460 cells were lysed and immunoprecipitated with an anti-p85 antibody or an anti-IRS1 antibody. The TIMM data show that E545K is enriched more than two-fold in the IRS1 complex. (C) The MS/MS fragmentation spectra via CID identifying the p110α WT and E545K somatic mutant peptide quantified from H460 cells. (D) The extracted ion chromatograms for the WT and E545K mutant p110α peptides. These represent the typical TIMM peak elution profile for targeted tryptic peptides using hybrid linear ion trap-orbitrap technology via LC/MS/MS.